Price History
Feb 9, 2026 — May 16, 2026Investment Snapshot
- Trading 147% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 0.5% — below-average profitability
- Revenue growing at 35% annually
TherapeuticsMD, Inc. - Common Stock (TXMD) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $23 million . Key value metrics: P/E ratio 159.6, P/B ratio 0.86, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
TherapeuticsMD, Inc. - Common Stock — Fundamental Analysis Summary
TherapeuticsMD, Inc. - Common Stock (TXMD) is currently trading 147% above its Graham Number of $0.81, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 159.6x.
On financial health, TXMD shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 0.5% (sector average: -20.6%).
StockPik's composite Value Score for TXMD is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
TXMD reports a high gross margin of 75.4% (sector average: 40.1%) and a negative operating margin of -178.9%.
TXMD shows revenue growing at 35% year-over-year, with earnings growing at 74%.